A related question.
Having found no dose-limiting toxicity with Cu67 attached to one targeting agent, can Clarity skip the dose escalatoon stage in therapeutic trials with Cu67 attached to different targeting agents?
Research/Valuation, page-205
-
- There are more pages in this discussion • 335 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.30 |
Change
-0.160(2.48%) |
Mkt cap ! $1.963B | |||
| Open | High | Low | Value | Volume |
| $6.30 | $6.37 | $6.21 | $8.318M | 1.326M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $6.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.30 | 4052 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |